← All trials
NCT02034279
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2014
- Primary completion
- Dec 31, 2016
- Completion date
- Feb 10, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 136
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- EASL - CLIF ConsortiumLead sponsor
- Leiden UniversityOverall official - principal investigator
- Medical University of GrazOverall official - principal investigator
- Osaka UniversityOverall official - principal investigator
- University of LondonOverall official - principal investigator
- University of CopenhagenOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of BernOverall official - principal investigator
- University of BonnOverall official - principal investigator
- University of MilanOverall official - principal investigator
- University of PadovaOverall official - principal investigator
- University of TurinOverall official - principal investigator
- National University of IrelandOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- Ludwig Maximilians UniversityOverall official - principal investigator
- Universidad de CordobaOverall official - principal investigator
- J. W. Goethe UniversityOverall official - principal investigator
- Aarhus UniversityOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Erasmus University RotterdamOverall official - principal investigator
- University of BolognaOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- University of Roma La SapienzaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.